| Literature DB >> 34068973 |
Pawel Kleczynski1, Jaroslaw Trebacz1, Maciej Stapor1, Robert Sobczynski2, Janusz Konstanty-Kalandyk2, Boguslaw Kapelak2, Krzysztof Zmudka1, Jacek Legutko1.
Abstract
Cardiac rehabilitation (CR) provides multifactorial support and intervention for cardiac patients and improves quality of life (QoL). We aimed to assess clinical performance and QoL changes in patients undergoing transcatheter aortic valve replacement (TAVR) scheduled directly to inpatient CR (CR group) and those who were discharged home (DH group). The following patient-related outcomes were recorded: 5 m walk time (5MWT), 6 min walk test (6MWT), handgrip strength (HGS) with dynamometer, Katz index of Independence of Activities in Daily Living (KI of ADL), Hospital Anxiety and Depression Scores (HADS) Score. Quality of life was evaluated with Kansas City Cardiomyopathy Questionnaire (KCCQ). Baseline data, 30-day and 6- and 12-month data were assessed. The CR group consisted of 52 patients and 53 were in the discharged home (DH group). When we compared outcomes between the groups, the 5MWT, 6MWT, HGS KI of ADL, and KCCQ were significantly better in the CR group at 30 days (p = 0.03, p = 0.01, p = 0.02, p = 0.048, respectively), and no difference was found in HADS scores. At 6 months, the effect of CR was sustained for 6MWT, HGS, KI of ADL, and KCCQ (p = 0.001, p = 0.001, p = 0.03, p = 0.003, respectively) but not for 5MWT. Interestingly, at 12 months, the CR group had better performance only in 6MWT and HGS compared with the DH group (p = 0.04, p = 0.03, respectively). We showed that inpatient CR is strongly associated with better clinical performance and QoL in patients undergoing TAVR. All patients may benefit from CR after TAVR. The most important aspect of inpatient CR after TAVR from the patient's perspective may be better performance in daily activities; however, performance was attenuated after 1 year.Entities:
Keywords: aortic valve stenosis; cardiac rehabilitation; frailty; transcatheter aortic valve replacement
Year: 2021 PMID: 34068973 PMCID: PMC8156110 DOI: 10.3390/jcm10102125
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Baseline clinical and echocardiographic characteristics.
| Variable | All ( | Cardiac Rehabilitation Group ( | Discharged Home Group ( | |
|---|---|---|---|---|
| Age, mean ± SD (years) | 80 ± 4.5 | 81 ± 4.9 | 80 ± 5.5 | 0.52 |
| Age ≥80 years | 24 (23%) | 13 (25%) | 11 (21%) | 0.48 |
| Men | 42 (40%) | 22 (42%) | 20 (38%) | 0.29 |
| Body mass index, median (IQR) (kg/m2) | 25.1 (23.7–27.6) | 23.9 (22.4–27.9) | 24.2 (23.0–28.3) | 0.73 |
| Estimated glomerular filtration rate, median (IQR) (mL/min/1.73 m2) | 52 (39.5–77.8) | 55 (39.9–75.1) | 54 (40.1–77.5) | 0.63 |
| NYHA class | ||||
| I + II | 0 | 0 | 0 | 0.49 |
| III | 76 (72%) | 39 (75%) | 37 (70%) | |
| IV | 29 (28%) | 14 (27%) | 15 (28%) | |
| Arterial hypertension | 96 (91%) | 47 (90%) | 49 (92%) | 0.25 |
| Diabetes mellitus | 47 (45%) | 22 (42%) | 25 (47%) | 0.34 |
| Atrial fibrillation | 28(27%) | 13 (25%) | 15 (28%) | 0.29 |
| Previous myocardial infarction | 39 (37%) | 19 (37%) | 20 (43%) | 0.53 |
| Previous percutaneous coronary intervention | 37 (35%) | 18 (35%) | 19 (36%) | 0.31 |
| Previous coronary artery bypass grafting | 15 (14%) | 7 (14%) | 8 (15%) | 0.32 |
| Chronic obstructive pulmonary disease | 18 (17%) | 10 (19%) | 8 (15%) | 0.13 |
| Peripheral artery disease | 25 (24%) | 12 (23%) | 13 (24%) | 0.29 |
| Stroke/transient ischemic attack | 18(17%) | 8 (15%) | 10 (19%) | 0.21 |
| Pacemaker | 11 (10%) | 6 (11%) | 5 (9%) | 0.72 |
| Logistic Euroscore II, median (IQR) | 9.9 (7.8–13.3) | 10.2 (7.9–13.5) | 9.9 (7.7–12.9) | 0.62 |
| The Society of Thoracic Surgeons score, median (IQR) | 8.2 (6.2–10.1) | 8.5 (6.1–10.5) | 7.9 (6.0–11.2) | 0.19 |
| Maximal transaortic gradient, mean ± SD (mmHg) | 82 ± 12.9 | 82 ± 16.5 | 84 ± 14.3 | 0.36 |
| Mean transaortic gradient, mean ± SD (mmHg) | 44 ± 4.5 | 45 ± 5.1 | 43 ± 6.2 | 0.31 |
| Aortic valve area, mean ± SD (cm2) | 0.7 ± 0.5 | 0.71 ± 0.3 | 0.72 ± 0.4 | 0.55 |
| Left ventricle ejection fraction, mean ± SD (%) | 50 ± 6.9 | 49 ± 9.4 | 50 ± 6.8 | 0.27 |
| Edwards Sapien 3 | 41 (39%) | 21 (40%) | 20 (38%) | 0.78 |
| Evolut R | 64 (61%) | 31 (60%) | 33 (62%) | 0.39 |
IQR, interquartile range; NYHA, New York Heart Association functional class; SD, standard deviation.
Study outcomes at baseline, 30 days, 6 months, and 12 months.
| Variable | Cardiac Rehabilitation Group ( | Discharged Home Group ( | |
|---|---|---|---|
| Outcomes at baseline | |||
| 5MWT, mean ± SD (seconds) | 6.8 ± 1.2 | 6.9 ± 1.3 | 0.86 |
| 6MWT, mean ± SD (meters) | 295 ± 42 | 283 ± 39 | 0.84 |
| HGS, mean ± SD (kg) | 26 ± 12.5 | 28 ± 13.1 | 0.76 |
| KI of ADL, mean ± SD (points) | 4.7 ± 1.2 | 4.6 ± 1.1 | 0.51 |
| HADS Anxiety, median (IQR) (points) | 6 (3–7) | 7(4–8) | 0.12 |
| HADS Depression, median (IQR) (points) | 2 (1–5) | 2(1–4) | 0.92 |
| KCCQ, mean ± SD (points) | 72.1 ± 21.1 | 73.5 ± 19.4 | 0.15 |
| Outcomes at 30 days | |||
| 5MWT, mean ± SD (seconds) | 5.1 ± 0.9 | 5.8 ± 1.3 | 0.03 |
| 6MWT, mean ± SD (meters) | 397 ± 24 | 384 ± 29 | 0.01 |
| HGS, mean ± SD (kg) | 36 ± 9.3 | 28 ± 12.1 | 0.02 |
| KI of ADL, mean ± SD (points) | 5.0 ± 0.8 | 4.8 ± 1.0 | 0.048 |
| HADS Anxiety, median (IQR) (points) | 2 (1–5) | 2 (1–6) | 0.82 |
| HADS Depression, median (IQR) (points) | 1 (1–3) | 1(1–4) | 0.12 |
| KCCQ, mean ± SD (points) | 82.5 ± 15.0 | 76.5 ± 12.4 | 0.04 |
| Outcomes at 6 months | |||
| 5MWT, mean ± SD (seconds) | 5.8 ± 1.0 | 5.9 ± 1.1 | 0.36 |
| 6MWT, mean ± SD (meters) | 426 ± 34 | 392 ± 19 | 0.001 |
| HGS, mean ± SD (kg) | 38 ± 7.3 | 30 ± 10.1 | 0.001 |
| KI of ADL, mean ± SD (points) | 5.0 ± 0.8 | 4.7 ± 1.2 | 0.03 |
| HADS Anxiety, median (IQR) (points) | 2 (1–5) | 2 (1–5) | 0.94 |
| HADS Depression, median (IQR) (points) | 1 (1–3) | 1 (1–4) | 0.17 |
| KCCQ, mean ± SD (points) | 86.5 ± 17.0 | 78.5 ± 11.4 | 0.03 |
| Outcomes at 12 months | |||
| 5MWT, mean ± SD (seconds) | 6.1 ± 0.9 | 6.3 ± 1.1 | 0.08 |
| 6MWT, mean ± SD (meters) | 410 ± 22 | 389 ± 18 | 0.04 |
| HGS, mean ± SD (kg) | 35 ± 10.5 | 30 ± 11.6 | 0.03 |
| KI of ADL, mean ± SD (points) | 5.1 ± 0.6 | 4.9 ±1.0 | 0.19 |
| HADS Anxiety, median (IQR) (points) | 2 (1–4) | 2 (1–4) | 0.92 |
| HADS Depression, median (IQR) (points) | 1 (1–3) | 1 (1–4) | 0.76 |
| KCCQ, mean ± SD (points) | 80.1 ± 18.5 | 77.4 ± 17.4 | 0.17 |
5MWT, 5m walk time; 6MWT, 6 min walk test; HGS, hand grip strength; KI of ADL, Katz index of Independence of Activities in Daily Living; HADS, Hospital Anxiety and Depression Scores; KCCQ, Kansas City Cardiomyopathy Questionnaire.